John Murphy, CEO, The COVID-19 Long Haul Foundation
Abstract
SARS-CoV-2 infection has been associated with delayed nail abnormalities including Beau’s lines, onychomadesis, transverse leukonychia, and chromonychia (“COVID nails”). These manifestations reflect systemic inflammatory, vascular, and metabolic stress affecting the nail matrix rather than direct viral invasion. This review synthesizes current evidence regarding the etiologic mechanisms, molecular and vascular pathophysiology, histopathologic correlates, clinical spectrum, and outcomes of COVID-19–associated nail disease.
1. Introduction
COVID-19–associated nail abnormalities are increasingly recognized as part of the post-acute dermatologic sequelae of SARS-CoV-2 infection. The nail unit functions as a slow-growing epithelial structure that records systemic physiological disturbances occurring weeks to months earlier.
Unlike cutaneous rashes seen during acute infection, nail findings are typically post-infectious markers of systemic stress, reflecting transient dysfunction of the nail matrix due to fever, hypoxia, inflammation, and microvascular injury.
2. Etiology
2.1 Indirect systemic mechanism
The prevailing model is that nail abnormalities arise from:
- Cytokine-mediated suppression of keratinocyte proliferation
- Fever-associated arrest of nail matrix growth
- Microvascular endothelial dysfunction
- Hypoxemia-induced metabolic stress
- Hospitalization-related physiologic stress
Direct infection of nail matrix cells has not been demonstrated.
2.2 Viral-host interaction pathways
SARS-CoV-2 induces systemic pathways relevant to nail pathology:
- ACE2 downregulation → angiotensin II excess → vasoconstriction
- IL-6, TNF-α, IL-1β elevation → keratinocyte growth arrest
- Endothelial activation → microthrombi formation
These systemic changes indirectly impair nail matrix function.
3. Pathophysiology
3.1 Nail matrix arrest syndrome
The nail matrix is highly mitotically active. Systemic stressors during COVID-19 can cause a temporary cessation of matrix proliferation, resulting in:
- Beau’s lines
- Onychomadesis (severe cases)
This mechanism is analogous to other febrile illnesses but more frequently reported due to the high global burden of SARS-CoV-2 infection.
3.2 Microvascular injury
COVID-19 causes endothelial dysfunction characterized by:
- Endothelial swelling
- Microthrombi formation
- Capillary rarefaction
- Perivascular inflammation
These changes reduce perfusion to the nail matrix and nail bed, contributing to:
- Transverse leukonychia
- Nail plate dyschromia
- Growth slowing
3.3 Inflammatory injury
Elevated cytokines impair keratinocyte function via:
- NF-κB pathway activation
- Oxidative stress
- Disruption of keratin filament assembly
4. Histopathology of COVID-19–Associated Nail Changes
Histopathologic data are limited but can be inferred from periungual biopsies and COVID-19 skin pathology studies.
4.1 Nail matrix histopathology
Reported and inferred findings include:
- Focal matrix keratinocyte apoptosis
- Reduced mitotic activity in germinal matrix
- Spongiosis in nail matrix epithelium (rare)
- Parakeratosis of nail plate formation zones
- Disruption of normal keratin filament alignment
These findings correlate with transient interruption of nail production.
4.2 Nail bed and periungual tissue
Common histopathologic features include:
- Endothelial swelling and vacuolization
- Perivascular lymphocytic infiltrates
- Microthrombi in superficial dermal vessels
- Deposition of complement components (C5b-9)
- Red cell extravasation in severe cases
These findings are consistent with COVID-19–associated systemic microangiopathy.¹
4.3 Vascular pathology
Electron microscopy and immunohistochemical studies in COVID-19 skin demonstrate:
- Endothelial cell injury with viral-like particles (controversial)
- Increased von Willebrand factor expression
- Platelet aggregation within dermal capillaries
These vascular changes plausibly extend to the nail unit, explaining ischemic nail matrix dysfunction.²
4.4 Comparison to other conditions
COVID-19 nail histology resembles:
- Severe febrile illness–associated Beau’s lines
- Kawasaki disease–associated nail bed inflammation
- Drug-induced nail matrix arrest
However, COVID-19 shows more prominent microvascular thrombotic features.
5. Clinical Nail Manifestations
5.1 Beau’s lines
Transverse depressions caused by temporary cessation of nail growth.
- Appear 2–8 weeks after infection
- Reflect timing of systemic insult
- Grow out with nail plate
5.2 Onychomadesis
Proximal nail shedding due to complete matrix arrest.
- More common in severe or hospitalized cases
- May affect multiple nails simultaneously
5.3 Transverse chromonychia (“COVID nails”)
Red, white, or mixed transverse bands likely due to:
- Vascular inflammation
- Temporary ischemia
- Keratinization disruption
5.4 Mees’ lines (leukonychia striata)
White transverse bands reflecting systemic toxicity or metabolic stress.
5.5 Nail growth retardation
Reduced nail growth rate persists for weeks to months after recovery.
6. Clinical Presentation
6.1 Timing
Nail changes appear delayed due to slow growth:
- Fingernails: 2–8 weeks post-infection
- Toenails: 6–12 weeks post-infection
6.2 Symptoms
Most patients are asymptomatic, with:
- Cosmetic nail changes
- Rare tenderness in periungual region
6.3 Distribution
- Often multiple fingernails
- Toenails less commonly but more persistently affected
7. Complications
- Cosmetic distress
- Anxiety and misdiagnosis as fungal disease
- Rare secondary onychomycosis due to nail disruption
- Chronic brittle nail syndrome in prolonged systemic illness
8. Therapeutic Approaches
8.1 General principles
No antiviral or disease-specific nail therapy is required.
8.2 Supportive management
- Nutritional optimization (protein, zinc, iron)
- Gentle nail care and protection
- Avoidance of trauma and harsh chemicals
8.3 Diagnostic caution
Important to exclude:
- Onychomycosis (KOH/culture)
- Psoriatic nail disease
- Drug-induced dystrophy
8.4 Dermatologic referral
Indicated for:
- Severe onychomadesis
- Persistent nail deformity
- Diagnostic uncertainty
9. Outcomes
9.1 Natural history
Most nail abnormalities are:
- Self-limited
- Fully reversible
Resolution timeline:
- Fingernails: 3–6 months
- Toenails: 6–12 months
9.2 Prognostic significance
Nail findings correlate loosely with:
- Severity of systemic inflammation
- Duration of fever
- Hospitalization or ICU admission
They may serve as a retrospective marker of disease severity.
9.3 Long-term outcomes
- Permanent nail damage: rare
- Recurrence: uncommon
- Persistent brittleness: occasionally reported in long COVID
10. Discussion
COVID-19 nail abnormalities represent a delayed epiphenomenon of systemic inflammatory and vascular injury rather than direct viral cytopathy. The nail matrix acts as a biologic recorder of systemic stress.
Histopathologic findings support a dual mechanism:
- Transient matrix arrest due to inflammatory cytokines
- Microvascular dysfunction with endothelial injury and microthrombi
This vascular-inflammatory paradigm aligns with broader COVID-19 pathophysiology affecting multiple organ systems.
11. Conclusion
SARS-CoV-2–associated nail changes are benign, delayed manifestations of systemic illness characterized by nail matrix growth arrest and microvascular dysfunction. Histopathology demonstrates keratinocyte suppression and endothelial injury rather than direct viral invasion. Recognition of these patterns aids clinical diagnosis and reinforces the systemic nature of COVID-19.
Footnotes / References
- Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Translational Research. 2020.
- Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–1418.
- Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020.
- Galván Casas C, et al. Classification of COVID-19 cutaneous manifestations. Br J Dermatol. 2020.
- Wollina U. COVID-19 and skin: a systematic review. Clin Dermatol. 2021.
- Daniel CR 3rd, et al. Beau lines and systemic disease: nail growth arrest physiology. Dermatol Clin. 2015.
- Piraccini BM, et al. Nail disorders in systemic disease. Lancet Dermatology Review. 2018.